Marshall Patrick 4

What Happened Marshall Patrick, a director of Edesa Biotech, was granted 19,000 restricted share units (RSUs) on 2026-05-27. The grant is reported as an award (transaction code A) at an acquisition price of $0.00 (no cash paid at grant). The filing was submitted to the SEC on 2026-05-29.

Key Details

• Transaction date: 2026-05-27; Form 4 filed: 2026-05-29 (timely within the usual 2-business-day window).
• Grant: 19,000 RSUs recorded at $0.00 acquisition price (total cash paid at grant = $0).
• Vesting: Per footnote, the RSUs vest in equal proportions over 12 months beginning on the grant date (monthly or quarterly vesting in equal parts over 12 months).
• Shares owned after transaction: Not specified in the filing.
• Reporting nuances: Footnote indicates Quidnet Inc. is wholly owned by the reporting person and the reporting person disclaims beneficial ownership of those securities except to the extent of his pecuniary interest.

Context This was an equity award (RSUs), not an open-market purchase or sale. RSUs represent a future right to receive shares subject to vesting; they are typically not evidence of an immediate buy/sell decision. The RSUs will convert to shares only as they vest according to the stated 12-month schedule.